Multiple Myeloma
From the Journals
Transplant beats bortezomib-based therapy for MM, but questions remain
From the Journals
Combo therapy with melflufen promising in small r/r multiple myeloma study
Feature
ASH tackles COVID-19 with hematology-related FAQ, promotes new registries
From the Journals
Frailty indexes fail in sorting elderly MM patients
Three different indexes had surprisingly little overlap in identifying frailty among older multiple myeloma patients.
From the Journals
First report of MM patient successfully treated for COVID-19 with tocilizumab
The patient presented with chest tightness and shortness of breath, indicating that symptoms of COVID-19 can be atypical in patients with...
Feature
Maintaining cancer care in the face of COVID-19
Oncologists are moving cancer patients to other hospitals, reevaluating the need for cancer treatments, and embracing telemedicine to protect...
From the Journals
Multiple myeloma treatment produces a similar survival benefit in very elderly patients
From the Journals
Fracture risk for MM patients remains higher despite improvements in treatments, survival
Despite new treatment strategies there was no decreased fracture risk for multiple myeloma patients over time.
Conference Coverage
Stored CD34 cells for multiple myeloma patients largely unused
ORLANDO –
News
FDA approves new drug for relapsed/refractory multiple myeloma
From the Journals
New CAR T-cell therapy eliminates MM and tumor propagating cells without fratricide in lab study
CD229 CAR T cells are highly active in vitro and in vivo against multiple myeloma plasma cells, memory B cells, and MM-propagating cells.